Plus Therapeutics Health Economics Study Shows 40% LM Cost Reduction
Plus Therapeutics’ health economics analysis indicates CNSide’s earlier CSF assay diagnosis may reduce leptomeningeal metastases healthcare costs by about 40%, with LM expenses topping $100,000 monthly and median inpatient admissions costing $20,000. The data support CNSide’s U.S. commercialization by demonstrating cost savings through earlier intervention and fewer hospitalizations.
1. Cost-of-Care Analysis Shows Significant Savings
The company’s health economics study projects that earlier detection and therapeutic management of LM using the CNSide CSF assay may cut overall LM healthcare costs by approximately 40%. The analysis cites median inpatient admissions of $20,000 and monthly LM-related expenses exceeding $100,000, with savings driven by earlier intervention, improved treatment precision, and fewer hospitalizations.
2. Implications for CNSide Commercialization
Demonstrating substantial cost reductions bolsters CNSide’s value proposition to payers and health systems as it enters U.S. commercialization. These economic benefits could accelerate assay adoption, support reimbursement negotiations, and enhance Plus Therapeutics’ commercial prospects in the CNS cancer diagnostics market.
3. Upcoming ISPOR 2026 Presentation
Plus Therapeutics will present the findings at the ISPOR 2026 Annual Meeting in Philadelphia, scheduled for May 17-20, 2026. The poster titled “Economic Impact of Earlier Detection and Therapeutic Management of Leptomeningeal Metastases Using CNSide” will highlight cost drivers, methodology, and potential quality-adjusted life year gains.